Notifiable Infectious Diseases Among Organ Transplant Recipients: A Data-Linked Cohort Study, 2000–2015

Karen M. J. Waller,1*, Nicole L. De La Mata,1 Kate R. Wyburn,1,2,3 James A. Hedley,1 Brenda M. Rosales,1 Patrick J. Kelly,1 Vidiya Ramachandran,4 Karan K. Shah,5 Rachael L. Morton,5 William D. Rawlinson,5,6 and Angela C. Webster1,5,7

1Collaborative Centre for Organ Donation Evidence, Sydney School of Public Health, Faculty of Health and Medicine, University of Sydney, Sydney, Australia, 2Department of Renal Medicine, Royal Prince Alfred Hospital, Camperdown, Australia, 3Sydney Medical School, Faculty of Health and Medicine, University of Sydney, Sydney, Australia, 4Serology and Virology Division, New South Wales Health Pathology Randwick, Prince of Wales Hospital, Randwick, Australia, 5National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, Australia, 6School of Medical Sciences, School of Biotechnology and Biomolecular Sciences, and School of Women’s and Children’s Health, University of New South Wales, Sydney, Australia, and 7Centre for Transplant and Renal Research, Westmead Hospital, Sydney, Australia

Background. Infections, including common communicable infections such as influenza, frequently cause disease after organ transplantation, although the quantitative extent of infection and disease remains uncertain.

Methods. A cohort study was conducted to define the burden of notifiable infectious diseases among all solid organ recipients transplanted in New South Wales, Australia, 2000–2015. Data linkage was used to connect transplant registers to hospital admissions, notifiable diseases, and the death register. Standardized incidence ratios (SIRs) were calculated relative to general population notification rates, accounting for age, sex, and calendar year. Infection-related hospitalizations and deaths were identified.

Results. Among 4858 solid organ recipients followed for 39183 person-years (PY), there were 792 notifications. Influenza was the most common infection (532 cases; incidence, 1358 [95% CI, 1247–1478] per 100 000 PY), highest within 3 months posttransplant. Next most common was salmonellosis (46 cases; incidence, 117 [95% CI, 87–156] per 100 000 PY), then pertussis (38 cases; incidence, 97 [95% CI, 71–133] per 100 000 PY). Influenza and invasive pneumococcal disease (IPD) showed significant excess cases compared with the general population (influenza SIR, 8.5 [95% CI, 7.8–9.2]; IPD SIR, 9.8 [95% CI, 6.9–13.9]), with high hospitalization rates (47% influenza cases, 68% IPD cases) and some mortality (4 influenza and 1 IPD deaths). By 10 years posttransplant, cumulative incidence of any vaccine-preventable disease was 12%, generally similar by transplanted organ, except higher among lung recipients. Gastrointestinal diseases, tuberculosis, and legionellosis had excess cases among transplant recipients, although there were few sexually transmitted infections and vector-borne diseases.

Conclusions. There is potential to avoid preventable infections among transplant recipients with improved vaccination programs, health education, and pretransplant donor and recipient screening.

Keywords. solid organ transplantation; immunosuppression; vaccine-preventable infections; gastrointestinal infections; sexually transmitted infections.
Although most (94%) hospitalizations and deaths due to communicable diseases in Australia are from nonnotifiable diseases [12], notifiable conditions are of public health importance and often have known preventive strategies. Understanding the epidemiology of notifiable infectious diseases within the vulnerable transplant recipient population informs the relative importance of these preventive strategies, including the potential to reduce hospitalizations and deaths. For instance, while vaccinations are internationally recommended for transplant recipients [13, 14], optimum vaccination strategies are still being refined given suboptimal immune responses to standard-dose vaccines [15]. In Australia, recommended vaccinations for solid organ recipients include hepatitis B, human papillomavirus, influenza (twice in first year posttransplant then yearly), pneumococcus (13-valent conjugate vaccine, then 2 doses of 23-valent polysaccharide vaccine), and diphtheria-tetanus-pertussis [16]. Poor uptake of vaccinations has been documented among organ recipients internationally [17, 18]. For other preventable infections, guidance on lifestyle measures to reduce infection risk is less evidence-based for transplant recipients [19, 20]. Both the provision of information to patients and patient adherence to recommendations vary [21, 22].

Data linkage of all transplant recipients to routinely collected health administrative data allows a long period of follow-up, to inform knowledge gaps about the epidemiology of infections posttransplant. We aimed to quantify the burden of notifiable infectious diseases in an Australian cohort of transplant recipients compared with the general population.

**METHODS**

A cohort study was performed among all solid organ recipients in NSW, Australia, transplanted from 2000 to 2015. This was used to estimate the burden of notifiable infectious diseases compared to the general population.

**Study Design**

Prospectively collected data in several state-based datasets were linked to form a comprehensive database of solid organ transplant recipients. The NSW Ministry of Health Biovigilance Public Health Register (SAFEBOD), described elsewhere [23], links transplant registers to administrative health data for all solid organ recipients in NSW (Supplementary Figure 1). SAFEBOD was initiated under the NSW Public Health Act and has ethical oversight from the University of Sydney Human Research Ethics Committee (project number 2016/758). In brief, deterministic and probabilistic data linkage were undertaken by the Centre for Health Record Linkage using best-practice privacy-preserving protocols. Matching was based on identifiers including name, sex, date of birth, postcode, and treating hospital. The error rate of linkage was estimated at <0.5% (maximum 5/1000 false positive or false negatives) [24]. Only de-identified data were available to researchers.

**Study Population**

Organ transplantation in Australia is coordinated at the state level. NSW, the most populous state, has 6 kidney transplant centers, 1 liver transplant center, and 1 lung/heart transplant center. In 2020, 379 organs were transplanted [25]. This study included all solid organ recipients resident in NSW transplanted between 1 January 2000 and 31 December 2015. Donor organs came from NSW and other states. Living and deceased donor transplants were included.

Characteristics of recipients included date of birth, sex, transplant date, and organs transplanted. Administrative health data of recipients were available until 31 December 2016 and included diagnostic codes, hospital and intensive care (ICU) admission dates, and dates and causes of death. To ascertain notifiable diseases occurring in recipients, the NSW-based NCIMS was used. All notifiable disease cases are reported under mandate by community and hospital pathology laboratories (who provide 99% of reports) and/or by doctors. Defined case criteria are applied, with duplicate records continuously sought and removed. Completeness of case ascertainment is expected to vary with disease type, severity, and diagnostic method (eg, mild influenza cases that do not seek medical attention will not be notified). Case data included infection type and site, disease onset date, and diagnosis method. Data for the general population were collated from publicly available NNDSS summary data [11]. Vaccination status was reported by NCIMS for some cases. However, full recipient vaccination data were unavailable as vaccines are typically administered in primary care and these data are not routinely collected.

**Outcomes**

The primary outcome was the incidence of notifiable infectious diseases. Secondary outcomes included hospitalizations, ICU admissions, and deaths following these infections.

**Definitions**

Notifiable infectious diseases reported between 2000 and 2016 were included, covering specified vaccine-preventable diseases, gastrointestinal diseases, STIs, vector-borne diseases, zoonoses, listed human diseases, and other bacterial infections (Table 1). Diseases that were not reportable in NSW or within the study period were excluded (campylobacteriosis, varicella zoster virus infection, respiratory syncytial virus) as case data were not available. Hepatitis B, hepatitis C, and human immunodeficiency virus were excluded as we have previously analyzed and reported these infections among this population [26]. Notified conditions not related to infectious diseases were excluded (lead poisoning).

Confirmed cases of notifiable disease were identified among recipients after transplant. To attribute a hospitalization or death to a specific infectious disease, the diagnosis codes for the healthcare episode listed a relevant infection International
Statistical Analyses

Demographic and clinical characteristics were compared between recipients with at least 1 notifiable disease and those without any notifiable diseases using χ² tests for categorical outcomes and Wilcoxon rank-sum test for continuous outcomes.

Infectious disease incidence rates per 100,000 person-years (PY) were estimated using multiple event survival analysis for each disease notification; recipients were observed from date of first transplant to date of death or end of follow-up (31 December 2016). Cumulative incidence was reported for disease groups with at least 50 notifications. Disease incidence among transplant recipients was compared with the general population using standardized incidence ratios (SIRs), estimated for each infection using indirect standardization, by age, sex, and calendar year. Statistical analyses were conducted in Stata 14.2 software (StataCorp, College Station, Texas).

RESULTS

Cohort Characteristics

There were 4858 solid organ recipients of 4968 organs during 2000–2015, followed for 39,183 PY (median, 7.5 PY). Most were males (63%) and kidney recipients (65%) (Table 2). The median age at transplant was 50 years (interquartile range [IQR], 36–58 years), with only 352 (7%) recipients <18 years of age.

At least 1 notifiable infectious disease was reported for 663 of 4858 recipients (14%). Recipients with notifiable diseases were younger than recipients without a notifiable disease (median age, 42 vs 50 years; P < .001). Although lung recipients formed only 11% of the total cohort, they were overrepresented (22%) among recipients with notifiable infections. Some transplant recipients had >1 infection notified; there were 792 notifications among these 663 recipients. Most notifications were vaccine-preventable diseases, predominantly influenza, followed by gastrointestinal diseases. There were few cases of STIs, vector-borne diseases, or other bacterial infections.

Table 1. Infectious Diseases Included in Our Cohort Study That Were Notifiable by Mandate for at Least Some of the Time Period 2000–2016

| Category                        | Infections (Years of Mandated Notification) |
|---------------------------------|--------------------------------------------|
| Vaccine-preventable diseases     | Diphtheria, Hib (invasive), influenza (2001+), measles, mumps, pertussis, poliomyelitis, IPD (2001+), rubella, and tetanus |
| Gastrointestinal diseases       | Botulism, cryptosporidiosis (2001+), cholera, hepatitis A, hepatitis E, giardiasis, listeriosis, rotavirus infection (2010+), salmonellosis, STEC infection/HUS, shigellosis, and typhoid fever |
| Sexually transmitted infections | Chlamydia, chancroid, donovanosis, gonococcal infection, lymphogranuloma venereum (2001+), and syphilis (2004+) |
| Vector-borne diseases and zoonoses | Anthrax (2001+), Barmah Forest virus infection, brucellosis (2015+), chikungunya virus infection (2008+), dengue virus infection, Flavivirus infection, Hendra virus infection (2012+), Japanese encephalitis virus infection (2001+), Kunjin virus infection (2001+), leptospirosis, Lyssavirus infection (2001+), malaria, Murray Valley encephalitis virus infection (2001+), psittacosis/ornithosis, Q fever, Ross River virus infection, tularemia (2003+), Zika virus |
| Listed human diseases           | Creutzfeldt-Jakob disease (2004+), MERS-CoV, plague, SARS, smallpox (2003+), viral hemorrhagic fevers, and yellow fever |
| Other bacterial infections      | Acute rheumatic fever (2001+)², legionellosis, leprosy, invasive meningococcal disease, rheumatic heart disease (<35 years old)², and tuberculosis |

Note: Infectable conditions not included in this study were blood-borne viruses (hepatitis B, C, and D, reported elsewhere [26]); conditions only monitored from 2017 onward (eg, respiratory syncytial virus); conditions not reportable in New South Wales (carmylobacteriosis, varicella zoster virus); and noninfectious notifiable conditions (lead poisoning).

Abbreviations: Hib, Haemophilus influenzae type b; HUS, hemolytic uremic syndrome; IPD, invasive pneumococcal disease; MERS-CoV, Middle East respiratory syndrome coronavirus; SARS, severe acute respiratory syndrome; STEC, Shiga toxinigenic Escherichia coli.

²Indicated by bracketed dates when notification was for part of the period only.
³Conditions indicated are reportable in New South Wales but not nationally and were included in this study.

Table 2. Participant Characteristics by Recipients With and Without Notifiable Infectious Disease

| Characteristic          | Recipients With At Least 1 Notification (Column %) | Recipients Without Notifiable Infectious Disease (Column %) | All Recipients (Column %) |
|-------------------------|---------------------------------------------------|-------------------------------------------------------------|---------------------------|
| Age, y                  | No. (row %)                                        | Recipients With At Least 1 Notification (Column %) | Recipients Without Notifiable Infectious Disease (Column %) | All Recipients (Column %) |
| <18                     | 112 (17)                                          | 240 (6)                                                      | 352 (7)                   |
| 18–34                   | 143 (22)                                          | 628 (15)                                                     | 771 (16)                  |
| 35–44                   | 106 (16)                                          | 673 (16)                                                     | 779 (16)                  |
| 45–54                   | 124 (19)                                          | 1074 (26)                                                    | 1198 (25)                 |
| ≥55                     | 142 (21)                                          | 1175 (28)                                                    | 1317 (27)                 |
| Organ type              | Male                                              | 2673 (64)                                                    | 3053 (63)                 |
| Kidney                  | Female                                            | 283 (43)                                                     | 1522 (36)                 |
| Liver                   | 388 (1)                                           | 881 (18)                                                     | 1409 (27)                 |
| Lung                    | 373 (56)                                          | 2767 (66)                                                    | 3140 (65)                 |
| Heart                   | 56 (8)                                            | 286 (7)                                                      | 342 (7)                   |
| Pancreas                | 11 (2)                                            | 61 (1)                                                       | 72 (1)                    |
| Year transplanted       | 2000–2003                                         | 147 (22)                                                     | 786 (19)                  |
| 2004–2007               | 169 (26)                                          | 927 (22)                                                     | 1096 (23)                 |
| 2008–2011               | 198 (30)                                          | 1101 (26)                                                    | 1299 (27)                 |
| 2012–2015               | 149 (22)                                          | 1381 (33)                                                    | 1530 (31)                 |

Data are presented as No. (%) unless otherwise indicated.

Abbreviation: IQR, interquartile range.
Abbreviations: CI, confidence interval; ICU, intensive care unit; IQR, interquartile range; LOS, length of hospital stay; PY, person-years; SIR, standardized incidence ratio.

4. type b infection, measles, poliomyelitis, rubella, or tetanus. and no cases of diphtheria, invasive

113) cases per 100 000 PY. There was only 1 case of mumps, by invasive pneumococcal disease (IPD) at 79 (95% CI, 56–

133) cases per 100 000 PY, followed

ond most common vaccine-preventable disease with an inci

97 (95% CI, 71–133) cases per 100 000 PY, followed

ring at a rate closer to the general population (SIR, 1.4 [95% CI, 1.0–1.9]), with an 11% hospitalization rate.

Excess cases of influenza dropped substantially over time, with the SIR reducing from 40.4 (95% CI, 22.4–73.0) in 2001–2004 to 6.6 (95% CI, 5.9–7.4) in 2013–2016 (Figure 2). Excess cases of pertussis also decreased over time and reached

The table below summarizes the incidence of notifiable infectious diseases among solid organ transplant recipients:

| Disease                        | Notifications/ Recipients, no./ % notification | Age, y, Median (IQR) | Incidence Rate per 100 000 PY (95% CI) | SIR (95% CI) | Hospitalization, No. (% Notification) | ICU Admission, No. (% Hospitalization) | LOS, d, Median (IQR) | Deaths, No. (% Notification) |
|--------------------------------|-----------------------------------------------|----------------------|----------------------------------------|-------------|---------------------------------------|----------------------------------------|---------------------|-----------------------------|
| Vaccine-preventable diseases   |                                               |                      |                                        |             |                                       |                                        |                     |                             |
| Influenzaa                      | 532/461 (27–59)                               | 45                    | 1358 (1247–1478)                      | 8.5 (7.8–9.2) | 250 (47)                              | 29 (12)                                | 4 (3–9)             | 4 (1)                       |
| Mumps                          | 1/1                                           | 63 (NA)               | 2.6 (4–18.1)                          | 2.5 (3–17.5) | 0 (0)                                 | ...                                    | ...                 | ...                         |
| Pertussis                      | 38/38 (32–57)                                 | 97 (71–133)           | 1.4 (1.0–1.9)                        | 4 (11)      | 0 (0)                                 | 6 (4–10)                           | 0 (0)                |                             |
| Pneumococcal diseaseb,c       | 31/28 (29–45)                                | 79 (56–113)           | 9.8 (6.9–13.9)                       | 21 (68)     | 6 (29)                                | 6 (4–10)                           | 1 (3)                |                             |
| Gastrointestinal diseases      |                                               |                      |                                        |             |                                       |                                        |                     |                             |
| Cryptosporidiosisc             | 32/31 (21–50)                                | 81 (57–115)           | 12.0 (8.5–17.0)                      | 14 (44)     | 1 (7)                                 | 9 (3–14)                           | 0 (0)                |                             |
| Giardiasis                     | 32/33 (36–61)                                | 84 (60–118)           | 3.4 (2.4–4.7)                        | 11 (33)     | 0 (0)                                 | 4 (3–11)                           | 0 (0)                |                             |
| Listeriosis                    | 5/5                                           | 61 (57–64)            | 34.1 (14.2–82.0)                     | 0 (0)       | ...                                   | ...                                 | 0 (0)                |                             |
| Rotavirus (2010+)              | 26/25 (4–38)                                 | 66 (45–97)            | 11.0 (7.5–16.2)                      | 14 (54)     | 0 (0)                                 | 4 (2–9)                            | 0 (0)                |                             |
| Salmonellosisc                 | 46/46 (29–56)                                | 117 (87–156)          | 2.8 (2.1–3.7)                        | 0 (0)       | ...                                   | ...                                 | 0 (0)                |                             |
| Shigellosisc                   | 2/2                                           | 55 (39–71)            | 5.1 (1.3–20.3)                       | 1.6 (4–6.6) | 0 (0)                                 | ...                                 | 0 (0)                |                             |
| Sexually transmitted infections|                                               |                      |                                        |             |                                       |                                        |                     |                             |
| Chlamydia                      | 5/4                                           | 34 (22–49)            | 0.1 (0–2)                            | 0 (0)       | ...                                   | ...                                 | 0 (0)                |                             |
| Gonococcal infection           | 4/4                                           | 40 (35–46)            | 0.2 (1–6)                            | 0 (0)       | ...                                   | ...                                 | 0 (0)                |                             |
| Syphilis (2004+)               | 7/7                                           | 54 (42–66)            | 2.0 (1.0–4.3)                        | 2 (29)      | 0 (0)                                 | 10 (9–11)                          | 0 (0)                |                             |
| Vector-borne diseases and zoonoses|                                             |                      |                                        |             |                                       |                                        |                     |                             |
| Ross River virus infection     | 4/4                                           | 57 (53–62)            | 0.4 (1–9)                            | 0 (0)       | ...                                   | ...                                 | 0 (0)                |                             |
| Psittacosis                    | 2/2                                           | 52 (45–58)            | 5.1 (1.3–20.3)                       | 9.0 (2.3–36.1) | 0 (0)                                 | ...                                 | 0 (0)                |                             |
| Other bacterial infections     |                                               |                      |                                        |             |                                       |                                        |                     |                             |
| Legionellosisc                 | 8/8                                           | 56 (53–64)            | 7.5 (3.7–15.0)                       | 5 (63)      | 1 (20)                                | 16 (13–19)                          | 0 (0)                |                             |
| Meningococcal diseaseb         | 1/1                                           | 58 (NA)               | 2.5 (4–18.0)                         | 3.7 (5–26.1) | 0 (0)                                 | ...                                 | 0 (0)                |                             |
| Tuberculosis                   | 15/15 (32–66)                                | 38 (23–63)            | 6.8 (4.1–11.2)                       | 8 (53)      | 2 (25)                                | 16 (14–33)                          | 1 (7)                |                             |

% notification: percentage of all notifications for that infection; % hospitalization: percentage of all hospitalizations for that infection.

Abbreviations: CI, confidence interval; ICU, intensive care unit; IQR, interquartile range; LOS, length of hospital stay; PY, person-years; SIR, standardized incidence ratio.

Each recipient may have multiple case notifications.

aRefers to invasive pneumococcal disease and invasive meningococcal disease.

**Vaccine-Preventable Diseases**

Influenza had by far the highest incidence of all notifiable infectious diseases posttransplant at 1358 (95% confidence interval [CI], 1247–1478) per 100 000 PY (Table 3). Most recipients (399/461) with influenza only had it once, but 55 of 461 were affected twice, and 7 recipients 3–4 times. Pertussis was the second most common vaccine-preventable disease with an incidence of 97 (95% CI, 71–133) cases per 100 000 PY, followed by invasive pneumococcal disease (IPD) at 79 (95% CI, 56–113) cases per 100 000 PY. There was only 1 case of mumps, and no cases of diphtheria, invasive *Haemophilus influenzae* type b infection, measles, poliomyelitis, rubella, or tetanus.

Compared with the general population, organ recipients were 8.5 times as likely to be diagnosed with influenza (SIR, 8.5 [95% CI, 7.8–9.2]) and 9.8 times as likely to be diagnosed with IPD (SIR, 9.8 [95% CI, 6.9–13.9]) (Figure 1). Many influenza (47%) and IPD (68%) cases were hospitalized, with the median length of stay 4 days for influenza and 6 days for IPD. Hospitalizations were sometimes associated with an ICU admission (12% influenza, 29% IPD). There were 4 deaths due to influenza (1% of cases) and 1 death (3% of cases) due to IPD. Recipients also experienced excess pertussis cases, occurring at a rate closer to the general population (SIR, 1.4 [95% CI, 1.0–1.9]), with an 11% hospitalization rate.

Excess cases of influenza dropped substantially over time, with the SIR reducing from 40.4 (95% CI, 22.4–73.0) in 2001–2004 to 6.6 (95% CI, 5.9–7.4) in 2013–2016 (Figure 2). Excess cases of pertussis also decreased over time and reached
general population rates from 2009 to 2012. Change in excess cases over time was less evident for IPD.

Vaccination status was poorly available (unknown for >95% cases). However, vaccination status was recorded for 16 of 28 (57%) patients with IPD, with 18 infections; only 44% (7/16) were vaccinated. The 11 infections in 9 unvaccinated recipients were associated with higher hospitalization rates than the 7 infections in vaccinated recipients (82% vs 29%; \( P = .03 \)).

Influenza incidence was highest in the first 3 months post-transplant (3047 [95% CI, 2208–4205] per 100 000 PY) (Figure 3). However, the cumulative incidence of vaccine-preventable diseases continued to increase with time (Figure 4A). By 10 years, 12% of recipients had experienced at least 1 vaccine-preventable disease. Influenza incidence was higher among lung transplant recipients than other organ recipients (Supplementary Table 2). Nearly 30% of lung recipients experienced a vaccine-preventable disease (mainly influenza) by 10 years posttransplant (Figure 4A). Younger organ recipients (≤29 years) had both higher influenza incidence and SIR than older recipients. Influenza type was poorly recorded (58% not otherwise specified), but influenza A was more common than influenza B (35% vs 6%).

**Gastrointestinal Diseases**

Salmonellosis was the second most common notifiable infectious disease and most common infectious gastrointestinal disease (incidence, 117 [95% CI, 87–156] per 100 000 PY). There were no cases of botulism, cholera, hepatitis A or E, Shiga-toxigenic *Escherichia coli*/hemolytic uremic syndrome, or typhoid fever.

All reported gastrointestinal diseases occurred more commonly than in the general population, except shigellosis, which was rare (Figure 1). Listeriosis had the highest SIR of any notifiable infectious disease (SIR, 34.1 [95% CI, 14.2–81.9]), followed by cryptosporidiosis (SIR, 12.1 [95% CI, 8.5–17.1]) and rotavirus infection (SIR, 11.0 [95% CI, 7.5–16.2]). The median age of rotavirus infection was low at 10 (IQR, 4–38). Giardiasis, cryptosporidiosis, and rotavirus infection had high hospitalization rates (33%–54%), but rarely resulted in ICU admissions and caused no deaths. By 10 years posttransplant, 3.4% of recipients (95% CI, 2.8–4.3) experienced a notifiable gastrointestinal infection (Figure 4A). Rates did not vary substantially by organ type.

**Sexually Transmitted Infections**

Sexually transmitted infections were rare, with few cases of chlamydia, gonorrhea, and syphilis. There was no chancroid, donovanosis, or lymphogranuloma venereum. Chlamydia and gonorrhea occurred less often than expected (chlamydia: SIR, 0.1 [95% CI, 0.0–0.2]; gonorrhea: SIR, 0.2 [95% CI, 0.1–0.6]); however, syphilis showed a slight excess in cases (SIR, 2.0 [95% CI, 1.0–4.3]). Many syphilis cases (29%) were associated with hospitalization, with significant lengths of stay (median, 10 days). Reactivation vs newly acquired syphilis could not be distinguished, as all cases were of unknown duration when notified.
Vector-Borne Diseases, Zoonoses, and Listed Human Diseases

Vector-borne diseases and zoonoses were also uncommon, with only 2 cases of psittacosis and 4 cases of Ross River virus infection recorded. Despite the few events, psittacosis occurred more often than expected (SIR, 9.0 [95% CI, 2.3–36.1]).

There were no cases of anthrax, Barmah Forest virus infection, brucellosis, chikungunya virus infection, dengue virus infection, Flavivirus infection, Hendra virus infection, Japanese encephalitis virus infection, Kunjin virus infection, leptospirosis, Lyssavirus infection, malaria, Murray Valley encephalitis virus infection, Q fever, tularemia, Zika virus infection, Creutzfeldt-Jakob disease, Middle East respiratory syndrome coronavirus, plague, severe acute respiratory syndrome, smallpox, viral hemorrhagic fevers, or yellow fever.

Other Bacterial Infections

Tuberculosis and legionellosis occurred infrequently but more commonly than in the general population (tuberculosis: SIR, 6.8 [95% CI, 4.1–11.2]; legionellosis: SIR, 7.5 [95% CI, 3.7–15.0]). Both were associated with high hospitalization rates (53%–63%), with median lengths of stay of 16 days, and some ICU admissions (20%–25%). There was 1 death attributed to tuberculosis. There was 1 case of invasive meningococcal disease and no cases of acute rheumatic fever, leprosy, or rheumatic heart disease (<35 years of age).

DISCUSSION

This study describes excess cases and health system impacts of notifiable infections among transplant recipients, including some rarely described elsewhere, and highlights opportunities for health promotion in this vulnerable group.

The excess burden of influenza and IPD highlights the importance of vaccinations for transplant recipients. Influenza risk was high immediately after transplant, but continued thereafter, suggesting the importance of ongoing vaccinations. Those at highest risk of influenza, hence the groups to target for prevention, were lung recipients and younger recipients, as in other studies [7, 27]. Higher rates of influenza among lung recipients may reflect increased testing for respiratory pathogens. Age-related differences may reflect vaccination rates, given that among “at risk” Australians aged 18–49 years in 2014, only 9.4% were vaccinated against influenza, compared with 45.3% of those aged >65 years [28]. Strategies for influenza vaccination posttransplant are debated, including high-dose or 2-dose vaccination regimens, as recipients may not mount adequate immune responses [15]. Pneumococcal vaccination recommendations also require further study [13, 29]. Our limited data suggest vaccination reduced IPD hospitalizations. Interestingly, the overall influenza case fatality rate was lower than reported elsewhere (0.75% vs 3.2%) [30]. This may reflect the relatively high proportion of cases in younger patients, differences in case identification (with this data-linkage study likely identifying less severe cases than those recruited from tertiary centers prospectively), and differences in attribution of death (our study uses ICD-10-AM codes to define deaths related to infection, rather than all-cause mortality).

Although already recommended by guidelines [31], our work adds emphasis to pertussis vaccination posttransplant, which is likely underreported elsewhere among organ recipients [32]. The reduction in excess influenza and pertussis cases over time could indicate improved vaccination, but this needs dedicated study. Changes in diagnostic techniques over time (from rapid antigen testing/viral culture to molecular testing) may increase the sensitivity or uptake of background community testing. Transplant recipient adherence to vaccination recommendations elsewhere are variable but have not been
reported in Australia [18]. Strategies to improve adherence to vaccinations among recipients include infectious diseases consultation [33], vaccination clinics [34], and improved communication [17, 35]. Understanding vaccination uptake and effectiveness in this cohort is of increasing relevance with the coronavirus disease 2019 pandemic, and transplant clinicians should be attentive to the full range of vaccines during follow-up.

We describe excess recipient gastrointestinal disease from viral, parasitic, and bacterial pathogens. High SIRs of foodborne bacterial diseases, including salmonellosis, were recently identified in another recipient cohort [36]. Interestingly, this occurs despite recommendations for trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis, which may impact infection rates [37]. For intestinal parasites or viruses, specific stool testing is required for diagnosis. Rotavirus is likely underestimated elsewhere as a cause of posttransplant diarrhea [38, 39] and affects more than infants. Health education could reduce incidence of infectious diarrhea [20], but there is currently no strong emphasis on food hygiene and hand hygiene in most clinical guidelines or patient information for solid organ recipients [19, 22]. A recent study on listeriosis notifications, mostly among immunocompromised persons, showed that most infected persons had recent exposure to high-risk foods, and few recalled receiving prior health education regarding food safety, suggesting room to improve health communication [40].

Legionellosis has known excess burden posttransplant [41], but psittacosis posttransplant has not been described. Recipients should be made aware of sources of and preventive behaviors for these infections, such as avoiding potting mix, evaporative air conditioners, spa baths, and birds [42].

Excess tuberculosis (well-described posttransplant) and syphilis cases (no prior rate estimates posttransplant) may relate to latent disease that has reactivated, although new and donor-derived infections are also possible [43–45]. Screening of donors and recipients for latent or active infection prior to transplantation enables recipient pretransplant treatment or posttransplant chemoprophylaxis [46, 47].

Low rates of chlamydia and gonorrhea, among the 5 most common notifiable diseases in Australia, are also remarkable [12]. Some case series detected increased asymptomatic STIs among recipients [48]. Relatively low notification rates could reflect lack of asymptomatic testing. Other explanations could include risk-reduction behavior (safer sex) or reduced exposure from sexual dysfunction associated with underlying disease or transplantation itself [49].

This study gives important insights into the relative incidence and severity of preventable infections among solid organ transplant recipients. Such diseases are frequently underreported in the literature, typically limited to case studies with severe outcomes. Prospective registries provide detailed infection data but lack a control population for comparison [27, 50]. In contrast, this work is a population-based sample observed over a long time frame, with objective detection measures standardized to a control population that considers change over time.

Limitations include that notification rates are a surrogate for true incidence, as they only reflect detected incidence of infections from those who seek medical attention and are subsequently diagnosed. Higher notification rates among transplant recipients could reflect more symptomatic disease rather than higher incidence, which remains of clinical significance. Notification rates in transplant recipients may also be
influenced by systematic differences in detection between recipients and the general population, due to higher rates of seeking medical care and test administration. Similarly, hospitalization rates may reflect more severe disease, more cautious medical care for immunosuppressed patients, or higher rates of hospitalization for other reasons. The nature of this study means some details of interest were not available, including vaccination status, education on risk factors, and specific exposures. Point estimates of incidence should be interpreted cautiously where case numbers were low. As infection

---

**Figure 4.** Cumulative incidence of infection after transplant. **A**, Vaccine-preventable and gastrointestinal infection among all recipients, with 95% confidence interval. **B**, Vaccine-preventable infections among recipients of each organ type. **C**, Numbers at risk for vaccine-preventable infections.
prevalence varies internationally, the incidences reported here are likely to vary from studies overseas; however, relative increases in incidence among transplant recipients compared with the general population rates would be expected to follow similar trends where immunosuppression and preventive strategies were similar. Importantly, nonnotifiable infectious diseases were not measured in this study, and notifiable infections are likely a minority of total recipient infectious disease burden [12, 50].

This study highlights areas where infection prevention may be improved for transplant recipients. We suggest a focus on improving vaccination rates and targeted research on optimum vaccination strategies, as well as education on food safety and other lifestyle modifications for immunosuppressed patients. Future studies should assess implementation of these strategies and develop clinician- and patient-focused interventions for improvement. Capturing all infections (including nonnotifiable infections) and assessing changes over time and across Australia would also be of interest.

There is potential to prevent burdensome infections among transplant recipients with improved vaccination programs (especially influenza and *Streptococcus pneumoniae*), health education (food and lifestyle safety), and donor and recipient screening for latent diseases.

**Supplementary Data**

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

**Notes**

**Acknowledgments.** We thank the New South Wales (NSW) Ministry of Health for providing in-kind support for data linkage and maintaining the Biovigilance Register. We also acknowledge the NSW Ministry of Health, the NSW Organ and Tissue Donation Service, the Australian and New Zealand Dialysis and Transplant Registry (ANZDATA), the Australian and New Zealand Islet and Pancreas Transplant Registry, the Australian and New Zealand Cardiothoracic Registry, the Australian and New Zealand Liver Transplant Registry, and the National Organ Matching System for the provision of data for this work. The Cause of Death Unit Record File (COD URF) is provided by the Australian Coordinating Registry for the COD URF on behalf of the NSW Registry of Births, Deaths and Marriages, the NSW Coroner, and the National Coronal Information System. We also thank the Centre for Health Record Linkage for assistance with data linkage. This work has been published on behalf of the NSW Ministry of Health Biovigilance Public Health Register (SAFEBOD) Study Group; Dr Michael O’Leary, Prof William Rawlinson, Prof Geoff McCaughan, Prof Anne Keogh, Prof Stephen McDonald, Prof David Currow, Prof Jeremy Chapman, Dr Lee Taylor, Ms Rebecca Hancock, and Dr Imogen Thomson.

**Author contributions.** K. M. J. W., N. L. D., and A. W. contributed to the concept development, interpretation of results, and presentation of findings. N. L. D., J. H., B. R., P. K., A. W., and K. W. sought and completed SAFEBOD data linkage, along with the SAFEBOD study group. K. M. J. W., N. L. D., and P. K. contributed to the statistical design. K. W., V. R., R. R., K. S., and R. M. contributed to concept development and interpretation of results. K. M. J. W. and N. L. D. performed statistical analysis. K. M. J. W. prepared the draft manuscript. All authors commented on the draft manuscript and approved the final manuscript for submission.

**Patient consent.** The design of this work has been approved by local ethics committees under the NSW Public Health Act and via the University of Sydney Human Research Ethics Committee (project number 2016/758). Written consent was waived due to the nature of this study.

**Data availability.** The data that support the findings of this study are not publicly available due to privacy and ethical restrictions. Reasonable requests to the corresponding author for access to data will be considered in conjunction with the relevant data custodians.

**Disclaimer.** Some of the data reported here have been supplied by ANZDATA. The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of ANZDATA.

**Financial support.** K. M. J. W. is funded by a National Health and Medical Research Council (NHMRC) Postgraduate Scholarship (GNT1168202). R. L. M. is supported by a University of Sydney Robinson Fellowship, and NHMRC investigator grant (1194703).

**Potential conflicts of interest.** The authors: No reported conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Hogan J, Pietrement C, Sellier-Leclerc AL, et al. Infection-related hospitalizations after kidney transplantation in children: incidence, risk factors, and cost. Pediatr Nephrol 2017; 32:2331–41.
2. Chan S, Pascoe EM, Clayton PA, et al. Infection-related mortality in recipients of a kidney transplant in Australia and New Zealand. Clin J Am Soc Nephrol 2019; 14:1484.
3. Fishman JA. Infection in organ transplantation. Am J Transplant 2017; 17: 856–79.
4. Nam HH, Ison MG. Community-acquired respiratory viruses in solid organ transplant.Curr Opin Organ Transplant 2019; 24:483–90.
5. Kumar D, Humar A, Plevenshi A, et al. Invasive pneumococcal disease in solid organ transplant recipients—10-year prospective population surveillance. Am J Transplant 2007; 7:1209–14.
6. Arslan H, Inci EK, Azap OK, Karakayali H, Torgay A, Haberal M. Etiologic agents of diarrhea in solid organ recipients. Transpl Infect Dis 2007; 9:270–5.
7. Feldman AG, Beaty BL, Curtis D, Juarez-Colunga E, Kempe A. Incidence of hospitalization for vaccine-preventable infections in children following solid organ transplant and associated morbidity, mortality, and costs. JAMA Pediatr 2019; 173:260–8.
8. Hamandi R, Law N, Alghamdi A, Husain S, Papadimitriou EA. Clinical and economic burden of infections in hospitalized solid organ transplant recipients compared with the general population in Canada—a retrospective cohort study. Transpl Int 2019; 32:1095–105.
9. European Centre for Disease Prevention and Control. The European Surveillance System (ESSy). 2021. https://www.ecdc.europa.eu/en/publications-data/european-surveillance-system-essy. Accessed 28 August 2021.
10. Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System (NNDSS). 2021. https://www.cdc.gov/nndss/index.html. Accessed 28 August 2021.
11. Australian Government Department of Health. National notifiable diseases surveillance system. 2020. http://www9.health.gov.au/cda/source/cda-index.cfm. Accessed 23 February 2020.
12. Australian Government Australian Institute of Health and Welfare. Australia’s health: infectious and communicable diseases. 2022. https://www.aihw.gov.au/reports/australias-health/infectious-and-communicable-diseases. Accessed 14 July 2022.
13. Danziger-Isakov L, Kumar D; AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13563.
14. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010; 77:299–311.
15. Haddadin Z, Krueger K, Thomas LD, Overton ET, Ison M, Halasa N. Alternative strategies of posttransplant influenza vaccination in adult solid organ transplant recipients. Am J Transplant 2021; 21:938–49.
16. Australian Government Department of Health. Australian immunisation handbook table. Recommended vaccines for people before and after a solid organ transplant. 2020. https://immunisationhandbook.health.gov.au/resources/handbook-tables/table-recommended-vaccines-for-people-before-and-after-a-solid-organ. Accessed 8 November 2020.

17. Lerchenfeldt SM, Cronin SM, Chandrasekar PH. Vaccination adherence in hematopoietic stem cell transplant patients: a pilot study on the impact of vaccination cards and reminder telephone calls. Transpl Infect Dis 2013; 15:634–8.

18. Larsen L, Bstrup C, Sørensen SS, Boesby L, Nguyen MTT, Johansen JS. The coverage of influenza and pneumococcal vaccination among kidney transplant recipients and waiting list patients: a cross-sectional survey in Denmark. Transpl Infect Dis 2021; 23:e13537.

19. Chadban S, Chan M, Fry K, et al. The CARI guidelines. Food safety recommendations for adult kidney transplant recipients. Nephrology 2010; 15(Suppl 1): S35–6.

20. Avery RK, Michaels MG. Strategies for safe living following solid organ transplantation—guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13519.

21. Lindup M, van den Bogaart L, Golshayan D, et al. Real-life food safety behaviour and incidence of foodborne infections in solid organ transplant recipients. Am J Transplant 2020; 20:1424–30.

22. McGeeney LM, Gattis GA. A survey of food safety information and foodborne infections post solid organ transplant. e-SPEN J 2014; 9:e195–9.

23. Rosales B, Hedley J, De La Mata N, et al. Safety and biovigilance in organ donation (SAFEROD): protocol for a population-based cohort study. JMIR Res Protoc 2020; 9:e18282.

24. Centre for Health Record Linkage. How record linkage works. 2019. http://www.cherel.org.au/how-record-linkage-works. Accessed 16 December 2019.

25. Australia and New Zealand Organ Donation Registry (ANZOD). 2021 annual report, section 2: overview of organ donation activity in Australia and New Zealand. Adelaide, Australia: ANZOD. 2021.

26. Waller KMJ, De La Mata NL, Hedley JA, et al. New blood-borne virus infections among organ transplant recipients: an Australian data-linked cohort study examining donor transmissions and other HIV, hepatitis C and hepatitis B notifications, 2000–2015. Transpl Infect Dis 2020; 22:e13437.

27. San Juan R, Aguado JM, Lumbreras C, et al. Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group. Am J Transplant 2007; 7:964–71.

28. Badros A, Menzies R. Using general practice data to monitor influenza vaccination coverage in the medically at risk: a data linkage study. BMJ Open 2019; 9:e031802.

29. Dendle C, Stuart RL, Mulley WR, Holdsworth SR. Pneumococcal vaccination in adult solid organ transplant recipients: a review of current evidence. Vaccine 2018; 36:6253–61.

30. Kumar D, Ferreira VH, Silveira F, et al. A 5-year prospective multicentre evaluation of influenza infection in transplant recipients. Clin Infect Dis 2018; 67: 1322–9.

31. Chong PP, Avery RK. A comprehensive review of immunization practices in solid organ transplant and hematopoietic stem cell transplant recipients. Clin Ther 2017; 39:1581–98.

32. Hovel EM, Pease RC, Scarano AJ, Chen DJ, Saddler CM. Bordetella pertussis in a four-time kidney transplant recipient: a call for immunization programs at transplant centers. Transpl Infect Dis 2019; 21:e13120.

33. Pineda EMZ, Spinner ML, Pallotta A, Koral C, Bollinger J. Infectious diseases pre-transplant evaluation improves vaccination rates for liver transplant candidates. Transpl Infect Dis 2019; 21:e13160.

34. Teh BW, Joyce T, Slavin MA, Thursky KA, Worth LJ. Impact of a dedicated post-transplant vaccination service at an Australian cancer centre. Bone Marrow Transplant 2017; 52:1681–3.

35. Dehnen D, Herwig A, Herzer K, Weltermann B. Improving the vaccination status of liver transplant patients: effectiveness of personally addressing patients and written recommendations to family physicians after 3 years. Transpl Infect Dis 2019; 21:e13140.

36. van den Bogaart L, Lang BM, Neefys D, et al. Epidemiology and outcomes of medically attended and microbiologically confirmed bacterial foodborne infections in solid organ transplant recipients. Am J Transplant 2022; 22:199–209.

37. Chadban SJ, Barraclough KA, Campbell SR, et al. KHA-CARI guideline: KHA-CARI adaptation of the KDIGO clinical practice guideline for the care of kidney transplant recipients. Nephrology 2012; 17:204–14.

38. Yin Y, Metselaar HJ, Sprenger D, Peppelenbosch MP, Pan Q. Rotavirus in organ transplantation: drug-virus-host interactions. Am J Transplant 2015; 15:585–93.

39. Stelzmueller I, Wiesmeyr S, Swenson BR, et al. Rotavirus enteritis in solid organ transplant recipients: an underestimated problem? Transpl Infect Dis 2007; 9: 281–5.

40. Leung K, Hope K, Sheppeard V. A review of listeriosis notifications and co-existing conditions in New South Wales, 2010–2015. Commun Dis Intell 2018; 42:S2209-6051(18)00019-2.

41. Sivagnanam S, Podczervinski S, Butler-Wu SM, et al. Legionnaires’ disease in transplant recipients: a 15-year retrospective study in a tertiary referral center. Transpl Infect Dis 2017; 19.

42. Sivagnanam S, Pergam SA. Legionellosis in transplantation. Curr Infect Dis Rep 2016; 18:9.

43. Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009; 48:1657–65.

44. Tanzicotti L, Das I, Dori L, Perera MT, Bramhall SR. Asymptomatic transmission of Treponema pallidum (syphilis) through deceased donor liver transplantation. Transpl Infect Dis 2012; 14:321–5.

45. Jensen TO, Darley DR, Goeman EE, Shaw K, Marriott DJ, Glanville AR. Donor-derived tuberculosis (TB): isoniazid-resistant TB transmitted from a lung transplant donor with inadequately treated latent infection. Transpl Infect Dis 2016; 18:782–4.

46. Len O, Garzoni C, Lumbreras C, et al. Recommendations for screening of donor and recipient prior to solid organ transplantation and to minimize transmission of donor-derived infections. Clin Microbiol Infect 2014; 20(Suppl 7):10–8.

47. Chadban SJ, Ahn C, Axelrod DA, et al. KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Transplantation 2020; 104(45 Suppl 1):S11–103.

48. Sarier M, Sepin Ozcn N, Guler H, et al. Prevalence of sexually transmitted diseases in asymptomatic renal transplant recipients [published online ahead of print 4 April 2018]. Exp Clin Transplant 2018. doi:10.6002/ect.2017.0232.

49. Burra P. Sexual dysfunction after liver transplantation. Liver Transpl 2009; 15(Suppl 2):S50–6.

50. van Delden C, Stampf S, Hirsch HH, et al. Burden and timeline of infectious diseases in the first year after solid organ transplantation in the swiss transplant cohort study. Clin Infect Dis 2020; 71:e159–69.